-+ 0.00%
-+ 0.00%
-+ 0.00%

Shanghai Henlius Biotech Secures NMPA Approval for Phase 2/3 Trials of HLX22 and HLX87 in HER2-Positive Breast Cancer

路透·12/09/2025 09:15:17

登錄查看新聞詳情